| Literature DB >> 20631869 |
Xiaomei Wei1, Tim S Bugni, Mary Kay Harper, Imelda T Sandoval, Elizabeth J Manos, Jennifer Swift, Ryan M Van Wagoner, David A Jones, Chris M Ireland.
Abstract
Three new minor components, the pyridoacridine alkaloidsEntities:
Keywords: Xestospongia cf. carbonaria; pyridoacridine alkaloids; zebrafish
Mesh:
Substances:
Year: 2010 PMID: 20631869 PMCID: PMC2901824 DOI: 10.3390/md8061769
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
1H and 13C-NMR data of pyridoacridine alkaloids (1–3).
| Posn. | 1 | 2 | 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| δH, mult ( | δC, mult | δH, mult ( | δC, mult | δH, mult ( | δC, mult | ||||
| 1 | 156.1 | C | 8.39, d (9.0) | 135.8 | CH | 8.19, d (9.0) | 143.0 | CH | |
| 2 | 7.48, d (8.0) | 116.5 | CH | 7.63, dd (9.0, 2.5) | 124.3 | CH | 7.73, dd (9.0, 7.5) | 128.4 | CH |
| 3 | 7.91, dd (8.0, 8.0) | 133.3 | CH | 162.7 | C | 7.84, dd (8.0, 7.5) | 133.5 | CH | |
| 4 | 8.45, d (8.0) | 114.5 | CH | 8.20, d (2.5) | 108.0 | CH | 9.27, d (8.0) | 125.1 | CH |
| 4a | 123.8 | C | 126.6 | C | 125.2 | C | |||
| 4b | 137.9 | C | 140.9 | C | 115.8 | C | |||
| 5 | 9.13, d (6.0) | 121.8 | CH | 9.00, d (6.0) | 122.9 | CH | 187.2 | C | |
| 6 | 9.37, d (6.0) | 150.2 | CH | 9.30, d (6.0) | 151.4 | CH | 4.41, s | 71.4 | CH2 |
| 7a | 147.0 | C | 149.5 | C | 115.1 | C | |||
| 8 | 180.0 | C | 180.6 | C | 161.0 | C | |||
| 8a | 130.3 | C | 130.8 | C | 132.7 | C | |||
| 9 | 9.87, s | 146.0 | CH | 9.82, s | 147.9 | CH | 9.72, s | 145.9 | CH |
| 11 | 9.40, d (6.5) | 147.8 | CH | 9.17, d (6.5) | 148.7 | CH | 8.75, d (6.5) | 142.0 | CH |
| 12 | 9.90, d (6.5) | 123.5 | CH | 9.38, d (6.5) | 124.1 | CH | 9.39, d (6.5) | 122.9 | CH |
| 12a | 147.9 | C | 149.2 | C | 143.5 | C | |||
| 12b | 143.1 | C | 145.5 | C | 139.5 | C | |||
| 12c | 120.1 | C | 120.8 | C | 129.9 | C | |||
| 13a | 134.4 | C | 141.5 | C | 143.1 | C | |||
| 14 | 4.57, s | 48.3 | CH3 | 4.58, s | 49.3 | CH3 | 4.53 | 49.0 | CH3 |
| 15 | 3.84, s (3H) | 54.1 | CH3 | ||||||
| 16 | 3.84, s (3H) | 54.1 | CH3 | ||||||
13C NMR data assigned based on the HSQC and HMBC in DMSO-d (500 MHz).
13C NMR data assigned based on the HSQC and HMBC in CD3OD (600 MHz).
13C NMR data assigned based on the HSQC and HMBC in CD3CN (500 MHz).
Figure 2Amphimedine-treated embryos exhibit heart, yolk and body shape defects. Treatment of embryos seven hours post-fertilization (hpf) with 30 μM amphimedine (amp) resulted in pericardial edema (arrow), extended heart (arrow head), enlarged yolk with thin extension (*), curving of the body and general necrosis at 24 hours post-treatment (hpt; B) and 48 hpt (D) compared to the DMSO-treated controls (A and C, respectively).
Figure 3Additional developmental defects resulting from amphimedine treatment. In situ hybridization was performed on control (A, C, E, G, I, K, M, O, Q) and treated (B, D, F, H, J, L, N, P, R) embryos harvested at 24 h (ntl, hnf6, myoD, dlx2, otx2, fgf8, zash1a, id6) or 48 h (crx) post treatment. Scale bars, 50 μM. not, notochord; sc, spinal cord; som, somites; pa, pharyngeal arches; fb, forebrain; mb, midbrain; mhb, mid/hindbrain boundary; hb, hindbrain; pfb, pectoral fin bud; e, eye.